Core Viewpoint - HireQuest, Inc. (HQI) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changing earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for HireQuest indicate an improvement in the company's underlying business, likely leading to an increase in stock price [5][10]. Zacks Rating System - The Zacks Rank stock-rating system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The system maintains a balanced distribution of "buy" and "sell" ratings, ensuring that only the top 20% of stocks receive a "Strong Buy" or "Buy" rating [9][10]. Earnings Estimate Revisions for HireQuest - For the fiscal year ending December 2025, HireQuest is expected to earn $0.64 per share, with no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for HireQuest has increased by 60%, reflecting positive sentiment among analysts [8].

Core Viewpoint - EVgo Inc. (EVGO) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the Zacks Consensus Estimate, which reflects EPS estimates from sell-side analysts for the current and following years [1][2]. - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for EVgo suggest an improvement in the company's underlying business, which could lead to increased stock prices as investors respond positively [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell) [7]. - Historically, Zacks Rank 1 stocks have generated an average annual return of +25% since 1988, indicating the effectiveness of the system [7]. - EVgo's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10]. Recent Performance of EVgo - For the fiscal year ending December 2025, EVgo is expected to earn -$0.41 per share, with no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for EVgo has increased by 15.3%, reflecting positive sentiment among analysts [8].

Group 1 - Fiverr International (FVRR) shares have increased by 1% over the past four weeks, closing at $22.33, with a mean price target of $31.9 indicating a potential upside of 42.9% [1] - The mean estimate consists of 10 short-term price targets with a standard deviation of $4.98, where the lowest estimate is $25.00 (12% increase) and the highest is $44.00 (97% increase) [2] - Analysts show strong agreement on FVRR's ability to report better earnings, with a positive trend in earnings estimate revisions, which is a strong predictor of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for FVRR has increased by 20% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - FVRR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement, which is useful for further research [14]

Core Viewpoint - TAL Education (TAL) has shown a 4% gain over the past four weeks, with a mean price target of $14.3 indicating a potential upside of 25.2% from the current price of $11.42 [1] Price Targets - The average price target consists of seven estimates ranging from a low of $11.54 to a high of $16.85, with a standard deviation of $1.83, suggesting variability in analyst predictions [2] - The lowest estimate indicates a modest increase of 1.1%, while the highest suggests a significant upside of 47.6% [2] - A low standard deviation indicates a higher agreement among analysts regarding price movement [9] Analyst Sentiment - Analysts are optimistic about TAL's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - The Zacks Consensus Estimate for the current year has increased by 52.1% over the past month, with three estimates revised upward and no negative revisions [12] - TAL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Q2 Holdings (QTWO) closed the last trading session at $71.72, gaining 21% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $92 indicates a 28.3% upside potential.The average comprises 14 short-term price targets ranging from a low of $74.00 to a high of $110.00, with a standard deviation of $11.37. While the lowest estimate indicates an increase of 3.2% from the current price level, ...

Core Viewpoint - Natural Gas Services (NGS) has shown a significant price increase of 13.4% over the past four weeks, with a mean price target of $38.25 indicating a potential upside of 29.3% from the current price of $29.58 [1] Price Targets and Analyst Consensus - The average price target for NGS ranges from a low of $34.00 to a high of $45.00, with a standard deviation of $4.99, suggesting a variability in estimates [2] - The lowest estimate indicates a 14.9% increase, while the highest suggests a 52.1% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, one estimate has increased, leading to a 9.5% rise in the Zacks Consensus Estimate for the current year [12] - NGS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - MBX Biosciences, Inc. (MBX) has shown significant stock price appreciation of 74.8% over the past four weeks, with a mean price target of $58.25 indicating a potential upside of 142% from the current price of $24.07 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $16.63, suggesting variability in analyst predictions. The lowest estimate is $30.00, indicating a 24.6% increase, while the highest estimate is $80.00, suggesting a 232.4% increase [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Consensus - Analysts have shown increasing optimism regarding MBX's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 2.7% over the past month, with three estimates increasing and no negative revisions [12] - MBX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Caution on Price Targets - While consensus price targets are often sought after, they can mislead investors, as empirical research shows that they rarely indicate actual stock price movements [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should approach price targets with skepticism and not rely solely on them for investment decisions [10][14]

Core Viewpoint - Electromed, Inc. (ELMD) shares have increased by 8.4% in the past four weeks, closing at $26.35, with a potential upside of 39.2% based on Wall Street analysts' mean price target of $36.67 [1][4]. Price Targets - The average price target for ELMD ranges from a low of $36.00 to a high of $38.00, with a standard deviation of $1.15, indicating a relatively tight clustering of estimates [2][9]. - The lowest estimate suggests a 36.6% increase from the current price, while the highest estimate indicates a 44.2% upside [2]. Analyst Sentiment - Analysts show strong agreement in revising earnings estimates higher, which historically correlates with positive stock price movements [4][11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 2.9%, with two estimates moving higher and no negative revisions [12]. Zacks Rank - ELMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a solid potential upside [13]. Conclusion on Price Targets - While the consensus price target may not be a reliable predictor of the exact price movement, it does provide a useful directional guide for potential stock performance [14].

Core Viewpoint - Gen Digital (GEN) shows potential for significant upside, with a mean price target of $34.38 indicating a 28.7% increase from its current price of $26.72 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $5.5, suggesting variability in analyst predictions. The lowest estimate is $29.00 (8.5% increase), while the highest is $46.00 (72.2% increase) [2][9]. - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown growing optimism regarding GEN's earnings prospects, as evidenced by a positive trend in earnings estimate revisions. This correlation between earnings revisions and stock price movements supports the expectation of an upside [11][12]. - Over the past 30 days, the Zacks Consensus Estimate for the current year has increased by 1.3%, with one estimate moving higher and no negative revisions [12]. Zacks Rank and Investment Potential - GEN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]. - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14].

Core Viewpoint - Eupraxia Pharmaceuticals Inc. (EPRX) shows potential for significant upside, with a mean price target of $11.1 indicating a 75.1% increase from its current price of $6.34 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $2.47, suggesting variability in analyst predictions. The lowest estimate is $6.58 (3.8% increase), while the highest is $14.00 (120.8% increase) [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about EPRX's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, two EPS estimates have increased while one has decreased, leading to a 16.1% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - EPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While the consensus price target may not be a reliable measure of potential gains, it does provide a useful guide for price movement direction [14]